Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Condition:   Metastatic Thyroid Cancer
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-Thyroglobulin mTCR PBL
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2015

  • Condition:   Solid Tumors
    Interventions:   Drug: Dasatinib;   Drug: Cyclophosphamide;   Drug: Temsirolimus
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting - verified March 2015

  • Conditions:   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
    Interventions:   Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
    Sponsors:   Emory University;   Children's Healthcare of Atlanta
    Recruiting - verified March 2015

  • Condition:   Human Immunodeficiency Virus (HIV)
    Interventions:   Drug: ZFN Modified CD4+ T Cells;   Drug: Cyclophosphamide
    Sponsors:   University of Pennsylvania;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified March 2015

  • Condition:   Metastatic Melanoma
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   John Wayne Cancer Institute
    Recruiting - verified February 2015

  • Conditions:   Distorted; Balance;   Quality of Life;   Neuropathy;   Cancer
    Intervention:  
    Sponsors:   The Institute of Physical Medicine and Rehabilitation;   Illinois CancerCare, P.C.;   University of Illinois College of Medicine at Peoria;   St. Francis Hospitals & Health Centers
    Recruiting - verified March 2015

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified February 2015

  • Condition:   Advanced Malignancies
    Interventions:   Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide
    Sponsor:   Regeneron Pharmaceuticals
    Recruiting - verified March 2015

  • Conditions:   Acute Leukemia;   Myelodysplasia
    Interventions:   Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Not yet recruiting - verified January 2015

  • Conditions:   Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsor:   Medical College of Wisconsin
    Recruiting - verified January 2015

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
    Interventions:   Drug: Oral Azacitidine;   Drug: Rituximab;   Drug: cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Celgene Corporation
    Recruiting - verified February 2015

  • Condition:   Breast Cancer
    Interventions:   Drug: Doxorubicin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: docetaxel;   Drug: Trastuzumab;   Drug: Pertuzumab
    Sponsor:   Western Regional Medical Center
    Recruiting - verified February 2015

  • Conditions:   Hematologic Malignancies;   Graft-Versus-Host Disease
    Intervention:   Biological: Activated PTCy-MILs
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified January 2015

  • Conditions:   Refractory Diffuse Large B Cell Lymphoma;   Refractory Primary Mediastinal B Cell Lymphoma;   Refractory Transformed Follicular Lymphoma
    Intervention:   Biological: KTE-C19
    Sponsor:   Kite Pharma, Inc.
    Recruiting - verified January 2015

  • Conditions:   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large B-cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   HIV Infection
    Interventions:   Drug: Prednisone;   Biological: Rituximab;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2015

  • Condition:   Neoplasm
    Interventions:   Genetic: SGT-53;   Drug: Topotecan;   Drug: Cyclophosphamide
    Sponsor:   SynerGene Therapeutics, Inc.
    Recruiting - verified January 2015

  • Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm to the Bone;   Metastatic Malignant Neoplasm to the Bone Marrow;   Metastatic Malignant Neoplasm to the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
    Interventions:   Drug: Vincristine Sulfate;   Drug: Doxorubicin Hydrochloride;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Etoposide;   Biological: Ganitumab;   Procedure: Therapeutic Surgical Procedure;   Radiation: Stereotactic Radiosurgery;   Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma
    Interventions:   Drug: AMP-224;   Radiation: Stereotactic Body Radiation Therapy(SBRT);   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: dexamethasone;   Drug: methotrexate;   Drug: cytarabine;   Drug: leucovorin calcium;   Drug: methylprednisolone;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   University of California, Davis;   Onyx Pharmaceuticals;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2014

  • Condition:   Lymphoma, Large B-Cell, Diffuse
    Interventions:   Drug: lenalidomide;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: prednisone;   Drug: vincristine
    Sponsor:   Celgene Corporation
    Recruiting - verified January 2015

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2014

  • Condition:   Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: NK Cells
    Sponsors:   M.D. Anderson Cancer Center;   The Leukemia and Lymphoma Society
    Recruiting - verified March 2015

  • Conditions:   Vaginal Cancer;   Cervical Cancer;   Anal Cancer;   Penile Cancer;   Oropharyngeal Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: E6 TCR;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified February 2015

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplasia
    Intervention:   Device: Alpha Beta T cell depletion
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting - verified December 2014

  • Conditions:   Bone Marrow Failure Syndromes;   Immunodeficiencies;   Immune Dysregulation Syndromes
    Intervention:   Device: CD3+/CD19+ delpletion using CliniMACs device follwing reduced intensity conditioning
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting - verified October 2014

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myelogenous Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: G-CSF;   Biological: Interleukin-2;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Biological: Natural killer cell therapy;   Biological: T-cell depleted HPC transplant;   Biological: CD45RA-depleted HPC transplant
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified October 2014

  • Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
    Interventions:   Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsors:   Dana-Farber Cancer Institute;   Pharmacyclics
    Recruiting - verified October 2014

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Previously Treated Metastatic Adenocarcinoma of the Pancreas
    Interventions:   Biological: CRS-207;   Biological: GVAX;   Drug: nivolumab;   Drug: CY
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Bristol-Myers Squibb;   Stand Up To Cancer;   Aduro BioTech;   AACR Research Acceleration Network
    Recruiting - verified September 2014

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Enzyme Inhibitor Therapy;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Radiation: Total-Body Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Adenocarcinoma of the Prostate
    Interventions:   Drug: Cyclophosphamide;   Biological: DRibble Vaccine;   Biological: HPV Vaccinations;   Drug: Imiquimod
    Sponsors:   UbiVac;   Providence Health & Services;   Providence Cancer Center;   Providence Cancer Center, Earle A. Chiles Research Institute
    Recruiting - verified September 2014

  • Condition:   Neuroblastoma
    Interventions:   Drug: Sorafenib;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   University of California, San Francisco;   Children's Hospital Los Angeles;   Lucile Packard Children's Hospital;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital of Philadelphia;   University of Michigan;   Seattle Children's Hospital;   Dana-Farber Cancer Institute;   The Hospital for Sick Children;   Children's Healthcare of Atlanta;   University of Chicago;   Cook Children's Health Care System;   Memorial Sloan Kettering Cancer Center.;   Children's Hospital Colorado
    Not yet recruiting - verified March 2015

  • Condition:   Human Immunodeficiency Virus (HIV)
    Interventions:   Genetic: SB-728mR-T;   Genetic: SB-728mR-T;   Drug: Cyclophosphamide
    Sponsor:   Sangamo Biosciences
    Recruiting - verified November 2014

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: MLN 9708;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Methotrexate
    Sponsors:   Massachusetts General Hospital;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified December 2014

  • Conditions:   Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;   Primary Effusion Lymphoma
    Interventions:   Drug: Pomalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified February 2015

  • Conditions:   Accelerated Phase of Disease;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Alkylating Agent-Related Acute Myeloid Leukemia;   Blastic Phase;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Graft Versus Host Disease;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Disease;   Refractory Anemia With Excess Blasts
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Fludarabine Phosphate;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified March 2015

  • Conditions:   Myeloma, Plasma-Cell;   Myeloma-Multiple
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Anti-BCMA CAR T cells
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse
    Interventions:   Drug: Tacrolimus (ARM with Methotrexate);   Drug: Tacrolimus (ARM with MMF and Cyclophosphamide);   Drug: Methotrexate (ARM with Maraviroc);   Drug: Methotrexate (ARM with Bortezomib);   Drug: Maraviroc;   Drug: Bortezomib;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Melanoma;   Sarcoma
    Interventions:   Drug: Ipilimumab;   Drug: Cyclophosphamide;   Biological: CD4+ T cells
    Sponsors:   M.D. Anderson Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2015

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Prednisone;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Dietary Supplement: Ascorbic acid;   Drug: PLD;   Drug: Lenalidomide
    Sponsors:   Oncotherapeutics;   Millennium: The Takeda Oncology Company
    Recruiting - verified October 2014

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Gemtuzumab Ozogamicin
    Sponsor:   New York Medical College
    Recruiting - verified August 2014

  • Condition:   Leukemia
    Interventions:   Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified January 2015

  • Condition:   Leukemia
    Interventions:   Procedure: ROR1R-CAR-T Cell Infusion;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Bendamustine
    Sponsors:   M.D. Anderson Cancer Center;   CLL Global Research Foundation Alliance
    Recruiting - verified February 2015

  • Conditions:   Hematologic Neoplasms;   Graft-Versus-Host Disease
    Intervention:   Device: Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
    Sponsor:   Ayman Saad
    Recruiting - verified November 2014

  • Condition:   Medulloblastoma
    Interventions:   Drug: Lomustine;   Drug: Vincristine;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified August 2014

  • Condition:   Hematological Malignancies
    Interventions:   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Biological: G-CSF;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Drug: Methylprednisolone;   Radiation: Total lymphoid irradiation;   Biological: Lymphocyte infusions
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified March 2015

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2015

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma
    Interventions:   Other: Clinical Observation;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MV-NIS
    Sponsor:   University of Arkansas
    Recruiting - verified March 2015

  • Conditions:   Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
    Interventions:   Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Ajai Chari;   Celgene Corporation
    Recruiting - verified June 2014

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Diamond Blackfan Anemia;   Non-malignant Hematologic Disorders
    Interventions:   Drug: Anti-thymocyte globulin (ATG);   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Mesna;   Radiation: total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified June 2014

  • Conditions:   Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
    Interventions:   Drug: Doxorubicin Hydrochloride;   Biological: Bleomycin Sulfate;   Drug: Vincristine Sulfate;   Drug: Etoposide;   Drug: Prednisone;   Drug: Cyclophosphamide;   Drug: Brentuximab Vedotin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   University of Pittsburgh
    Recruiting - verified February 2015

  • Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis II;   Mucopolysaccharidosis VI;   Mucopolysaccharidosis VII;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Glycoprotein Metabolic Disorders;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy;   Peroxisomal Disorders;   Osteopetrosis;   Rett Syndrome;   Sphingolipidosis;   Gangliosidosis;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann Pick B;   Niemann Pick C Subtype 2;   I-cell Disease
    Interventions:   Procedure: blood stem cell transplant;   Drug: Rabbit Anti-Thymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A (CSA);   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte-Colony Stimulating Factor (G-CSF);   Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Drug: N-acetylcysteine;   Drug: Celecoxib;   Drug: Vitamin E;   Drug: Alpha Lipoic Acid
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified June 2014

  • Conditions:   Primary Graft Failure;   Secondary Graft Failure
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Hematopoietic stem cell infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified June 2014

  • Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: IPI-145;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsors:   Dana-Farber Cancer Institute;   Infinity Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: cyclophosphamide;   Biological: anti CD123-CAR/CD28-costimulatory, retroviral vector-transduced autologous T lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified January 2015

  • Conditions:   Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
    Intervention:   Drug: MLN9708
    Sponsors:   Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2015

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Metastatic Cancer;   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Acute Leukemias;   Burkitt's Lymphoma;   Chronic Myelogenous Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Haploidentical stem cell transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified May 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: 5-fluorouracil;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin;   Drug: epirubicin;   Drug: paclitaxel;   Drug: pertuzumab [Perjeta];   Drug: trastuzumab [Herceptin]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified March 2015

  • Conditions:   Metastatic Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified May 2014

  • Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: Viagenpumatucel-L;   Drug: Metronomic Cyclophosphamide;   Drug: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
    Sponsor:   Heat Biologics
    Recruiting - verified November 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Not yet recruiting - verified September 2014

  • Conditions:   Myeloablative Conditioning;   HLA-mismatched Bone Marrow Transplantation
    Interventions:   Drug: Post-transplantation Cyclophosphamide;   Radiation: TBI cGy;   Drug: Busulfan;   Other: Bone Marrow Infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified April 2014

  • Conditions:   Hematopoietic/Lymphoid Cancer;   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: Olanzapine;   Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);   Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant);   Other: Placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Malignant Rhabdoid Tumor;   Atypical Teratoid Rhabdoid Tumor
    Interventions:   Drug: alisertib;   Drug: methotrexate;   Drug: cisplatin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: topotecan;   Drug: vincristine;   Procedure: Surgical resection;   Radiation: Radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Conditions:   Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Daunorubicin Hydrochloride;   Drug: Pegaspargase;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Doxorubicin Hydrochloride;   Drug: Thioguanine;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Drug: Leucovorin Calcium;   Drug: Etoposide;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Metastatic Cancer That Express the MAGE-A3-DP4 Antigen
    Interventions:   Biological: Anti-MAGE-A3-DP4 TCR;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Melanoma
    Interventions:   Biological: Anti-GD2-CAR engineered T cells;   Drug: AP1903;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Stem Cell Transplantation;   Graft vs Host Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Radiotherapy
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
    Recruiting - verified January 2015

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: T Regulatory cells;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Not yet recruiting - verified April 2014

  • Conditions:   Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: NK cells;   Biological: IL-2;   Drug: INCB024360
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Incyte Corporation
    Recruiting - verified April 2014

  • Conditions:   Melanoma;   Skin Cancer
    Interventions:   Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
    Interventions:   Drug: etoposide;   Drug: cyclophosphamide;   Radiation: total marrow irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
    Interventions:   Drug: Simvastatin;   Drug: Doxorubicin/cyclophosphamide
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified February 2015

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified October 2014

  • Condition:   Hematologic Malignancies
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting - verified November 2014

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
    Sponsors:   New York Medical College;   St. Baldrick's Foundation
    Recruiting - verified September 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: carfilzomib;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Lupus Erythematosus;   Graft-versus-host Disease
    Interventions:   Drug: Cyclophosphamide;   Drug: Sodium-2-mercapto ethane sulphonate;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mofetil;   Drug: Rabbit antithymocyte globulin
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2014

  • Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Biological: aldesleukin;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting - verified March 2015

  • Conditions:   Metastatic Cancer;   Metastatic Melanoma
    Interventions:   Biological: Anti-NY ESO-1 TCR CD62L+ cells;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
    Recruiting - verified December 2014

  • Conditions:   Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Biological: genetically engineered NY-ESO-1-specific T lymphocytes;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: busulfan;   Drug: fludarabine phosphate;   Radiation: total-body irradiation (TBI);   Procedure: Stem cell transplant;   Drug: cyclophosphamide
    Sponsor:   Washington University School of Medicine
    Recruiting - verified February 2015

  • Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: CHOP;   Drug: GDC-0199;   Drug: obinutuzumab;   Drug: rituximab [MabThera/Rituxan]
    Sponsors:   Hoffmann-La Roche;   AbbVie
    Recruiting - verified March 2015

  • Conditions:   Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
    Interventions:   Drug: Ibrutinib;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Biological: Rituximab;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
    Interventions:   Biological: H1299 Lysate Vaccine;   Drug: Cyclophosphamide;   Drug: Celecoxib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Acute Lymphocytic Leukemia;   Adult Lymphoblastic Lymphoma
    Interventions:   Drug: DNR;   Drug: VCR;   Drug: PEG-asp;   Drug: CTX;   Drug: Prednisone;   Drug: Liposomal AraC;   Drug: MTX;   Drug: LCV;   Drug: AraC;   Drug: Etoposide;   Drug: Dasatinib;   Drug: Rituximab;   Drug: Hydrocortisone
    Sponsors:   University of California, San Diego;   Sigma Tau Pharmaceuticals, Inc.
    Recruiting - verified December 2014

  • Condition:   Neuroblastoma
    Interventions:   Drug: DFMO;   Drug: Celecoxib;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Procedure: CD8+ T Cells;   Drug: Interleukin-2;   Drug: Ipilimumab
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas;   American Association for Cancer Research
    Recruiting - verified February 2015

  • Condition:   Kidney Transplantation
    Interventions:   Biological: Antithymocyte globulin (ATG);   Drug: Fludarabine;   Drug: Low dose Pre-transplant cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Methylprednisolone;   Biological: Bone Marrow;   Drug: MESNA;   Drug: Mycophenolate mofetil (MMF);   Drug: Prednisone;   Drug: Filgrastim;   Drug: High dose post-transplant cyclophosphamide
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified October 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Ixazomib (MLN9708);   Drug: Dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo;   Drug: Placebo
    Sponsors:   AbbVie;   United States Oncology;   NSABP Foundation Inc;   Grupo Espanol de Investigacion del Cancer de Mama;   Austrian Breast & Colorectal Cancer Study Group;   Alliance for Clinical Trials in Oncology;   German Breast Group
    Recruiting - verified January 2015

  • Conditions:   Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
    Intervention:   Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
    Sponsors:   Merrimack Pharmaceuticals;   South Plains Oncology Consortium (SPOC)
    Recruiting - verified December 2014

  • Condition:   Untreated Childhood Medulloblastoma
    Interventions:   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Etoposide;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Other: Cognitive Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Sickle Cell Disease
    Interventions:   Procedure: Haploidentical Transplant;   Drug: Alemtuzumab;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Sirolimus
    Sponsor:   Damiano Rondelli, MD
    Recruiting - verified December 2014

  • Condition:   Breast Cancer
    Interventions:   Biological: DC vaccination+Preop chemotherapy;   Biological: DC vaccination+Preop chemo+anakinra
    Sponsor:   Baylor Research Institute
    Recruiting - verified June 2014

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Blinatumomab;   Drug: Etoposide;   Drug: Prednisone;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (young TIL)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Dexamethasone;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Hematopoietic/Lymphoid Cancer
    Interventions:   Radiation: Total-Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified November 2014

  • Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
    Intervention:   Drug: Cyclophosphamide
    Sponsor:   Racquel Innis-Shelton, MD
    Recruiting - verified August 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsor:   Onyx Therapeutics, Inc.
    Recruiting - verified March 2015

  • Condition:   Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PCI-32765 (Ibrutinib);   Drug: Placebo
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics
    Recruiting - verified March 2015

  • Condition:   Lymphoma, B-Cell, Non-Hodgkin's Lymphoma
    Interventions:   Drug: DCDS4501A;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: prednisone;   Drug: rituximab [MabThera/Rituxan]
    Sponsor:   Genentech, Inc.
    Recruiting - verified March 2015

  • Condition:   2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
    Interventions:   Biological: GVAX Pancreas Vaccine;   Biological: CRS-207;   Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib;   Drug: cyclophosphamide
    Sponsor:   Aduro BioTech, Inc.
    Recruiting - verified February 2015

  • Condition:   Metastatic Cancers Other Than Melanoma That Express ESO Antigen
    Interventions:   Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Metastatic Beast Cancer
    Interventions:   Drug: Exemestane;   Drug: Cyclophosphamide
    Sponsor:   New York University School of Medicine
    Recruiting - verified December 2014

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified May 2014

  • Condition:   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Smac Mimetic LCL161;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   CPRIT
    Recruiting - verified February 2015

  • Conditions:   Desmoplastic Small Round Cell Tumor;   Ewing Sarcoma of Bone or Soft Tissue;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Interventions:   Drug: vincristine;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: temozolomide;   Drug: temsirolimus;   Drug: bevacizumab;   Drug: sorafenib;   Procedure: surgery;   Radiation: radiation
    Sponsors:   St. Jude Children's Research Hospital;   University of Tennessee Health Science Center;   University of Florida;   Nemours Children's Clinic
    Recruiting - verified February 2015

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Radiation: stereotactic body radiation therapy;   Drug: cyclophosphamide;   Biological: therapeutic autologous lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   Stanford University;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   DLBCL;   Lymphoma, B-cell;   Lymphoma, Large B-cell, Diffuse
    Interventions:   Drug: brentuximab vedotin;   Drug: brentuximab vedotin;   Drug: rituximab;   Drug: vincristine;   Drug: cyclophosphamide;   Drug: prednisone;   Drug: doxorubicin
    Sponsor:   Seattle Genetics, Inc.
    Recruiting - verified February 2015

  • Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Biological: trastuzumab;   Biological: bevacizumab;   Drug: docetaxel;   Drug: carboplatin;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Breast Cancer;   Adenocarcinoma of the Breast
    Interventions:   Radiation: PBI;   Other: PBI with chemotherapy
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified June 2014

  • Conditions:   Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
    Interventions:   Drug: brentuximab vedotin;   Drug: etoposide;   Drug: prednisone;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: Dacarbazine(R);   Drug: filgrastim;   Procedure: quality of life assessment;   Radiation: radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   Seattle Genetics, Inc.
    Recruiting - verified January 2015

  • Condition:   Leukemia
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PEG-Asparaginase;   Drug: Methotrexate;   Drug: 6-MP (6-Mercaptopurine);   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Leucovorin;   Drug: Dexamethasone
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Sigma-Tau Research, Inc.;   Duke University;   Weill Medical College of Cornell University
    Recruiting - verified January 2015

  • Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Cyclophosphamide;   Biological: DRibble vaccine;   Drug: Imiquimod;   Drug: GM-CSF;   Biological: HPV vaccine
    Sponsors:   UbiVac;   National Cancer Institute (NCI);   Providence Cancer Center, Earle A. Chiles Research Institute;   Providence Health & Services;   Mayo Clinic;   Louisiana State University Health Sciences Center in New Orleans
    Recruiting - verified December 2014

  • Conditions:   Leukemia;   Myeloproliferative Diseases
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Radiation: Total Body Irradiation (TBI)
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2015

  • Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: paclitaxel;   Biological: trastuzumab;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Cytokine-induced killer cells;   Biological: Aldesleukin
    Sponsor:   Washington University School of Medicine
    Recruiting - verified February 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Oprozomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
    Sponsor:   Onyx Therapeutics, Inc.
    Recruiting - verified March 2015

  • Condition:   Medulloblastoma
    Interventions:   Radiation: Craniospinal Irradiation with boost to the primary tumor site;   Drug: Cyclophosphamide;   Drug: Cisplatin;   Drug: Vincristine;   Drug: Vismodegib;   Drug: Pemetrexed;   Drug: Gemcitabine;   Other: Aerobic Training;   Other: Neurocognitive Remediation
    Sponsors:   St. Jude Children's Research Hospital;   Genentech, Inc.
    Recruiting - verified January 2015

  • Conditions:   HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: lapatinib ditosylate;   Biological: trastuzumab;   Other: laboratory biomarker analysis
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Rhabdomyosarcoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified January 2015

  • Condition:   Malignant Neoplasm
    Interventions:   Radiation: Total-body irradiation;   Biological: Donor lymphocytes infusion (DLI);   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified December 2014

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: ixazomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Solid Tumors;   Brain Tumors;   Sarcoma;   Wilm's Tumor;   Rhabdomyosarcoma
    Interventions:   Biological: Recombinant human interleukin-15 (rhIL-15);   Biological: NK Cell Infusion
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Newly Diagnosed Ewing Sarcoma
    Interventions:   Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*;   Drug: Temozolomide;   Drug: Irinotecan
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified January 2015

  • Condition:   Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone (or equivalent)
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics
    Recruiting - verified March 2015

  • Conditions:   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Relapsed B-Cell Acute Lymphoblastic Leukemia
    Interventions:   Procedure: leukapheresis or collection of PBMCs;   Drug: cyclophosphamide;   Biological: modified T cells
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital
    Recruiting - verified March 2015

  • Condition:   Hodgkin Disease
    Interventions:   Drug: ABVE-PC;   Drug: DECA
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified March 2015

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting - verified February 2015

  • Conditions:   GATA2;   Immunodeficiency;   MDS
    Interventions:   Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine Anti-Thymocyte Globulin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Hematological Malignancy
    Interventions:   Drug: Cohort 1-Bortezomib (Velcade ®);   Drug: Cohort 2-Bortezomib (Velcade ®);   Drug: Cohort 3-Bortezomib (Velcade ®)
    Sponsors:   Spectrum Health Hospitals;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2015

  • Conditions:   Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
    Sponsors:   University of Iowa;   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Sickle Cell Disease;   Hemoglobinopathies
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting - verified July 2014

  • Condition:   Locally Advanced Breast Cancer
    Interventions:   Drug: Propranolol;   Other: Breast imaging - Diffuse Optical Tomography (DOT);   Drug: Paclitaxel;   Drug: Nab-paclitaxel;   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsor:   Columbia University
    Recruiting - verified February 2015

  • Conditions:   Crohn's Disease;   Crohn Disease
    Intervention:   Drug: High-dose Cyclophosphamide
    Sponsor:   Johns Hopkins University
    Recruiting - verified March 2015

  • Condition:   Peripheral T-cell Lymphoma
    Interventions:   Drug: Belinostat;   Drug: CHOP
    Sponsor:   Spectrum Pharmaceuticals, Inc
    Recruiting - verified March 2015

  • Condition:   Juvenile Myelomonocytic Leukemia
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: melphalan;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
    Sponsor:   New York Medical College
    Recruiting - verified September 2014

  • Condition:   Neuroblastoma
    Interventions:   Genetic: iC9-GD2 T Cell Lymphocytes-frozen cells;   Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: pembrolizumab
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Solving Kids’ Cancer;   The EVAN Foundation;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Childhood Cerebral Adrenoleukodystrophy;   (X-linked Adrenoleukodystrophy Cerebral Childhood)
    Interventions:   Genetic: Lenti-D Drug Product;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Filgrastim
    Sponsor:   bluebird bio
    Recruiting - verified October 2014

  • Conditions:   Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Therapeutic Tumor Infiltrating Lymphocytes;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenylate mofetil
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified October 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy;   Radiation: Radiation Therapy
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified February 2015

  • Condition:   Retinoblastoma
    Interventions:   Drug: vincristine;   Drug: topotecan;   Drug: filgrastim;   Drug: PEG-filgrastim;   Drug: carboplatin;   Other: focal therapy - stratum B and D;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: MESNA;   Drug: doxorubicin;   Procedure: enucleation;   Radiation: external beam radiation;   Other: focal therapy - strata A
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified January 2015

  • Conditions:   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
    Interventions:   Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Drug: cyclophosphamide
    Sponsors:   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2015

  • Condition:   Breast Neoplasms
    Interventions:   Drug: Doxorubicin;   Biological: Trastuzumab;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Fluorouracil
    Sponsor:   Washington University School of Medicine
    Recruiting - verified February 2015

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified February 2015

  • Conditions:   Burkitt Lymphoma;   Burkitt Leukemia;   Diffuse Large B Cell Lymphoma;   Post Transplant Lymphoproliferative Disorder;   Primary Mediastinal (Thymic) Large B-cell Lymphoma
    Interventions:   Drug: DA-EPOCH-R for BL and B-ALL;   Drug: Methotrexate;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: G-CSF;   Drug: DA-EPOCH-R for DLBCL, PTLD & PMBCL
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI);   Texas Children's Hospital
    Recruiting - verified December 2014

  • Conditions:   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Biological: Palifermin;   Biological: Lupron;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total-Body Irradiation (TBI);   Drug: Thiotepa;   Drug: Cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Swedish Orphan Biovitrum
    Recruiting - verified January 2015

  • Condition:   Melanoma
    Interventions:   Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Prometheus Laboratories;   Key Biologics, LLC
    Recruiting - verified January 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Velcade;   Drug: Cyclophosphamide;   Drug: Revlimid
    Sponsors:   Duke University;   Millennium Pharmaceuticals, Inc.;   Duke Cancer Institute
    Recruiting - verified July 2014

  • Condition:   Chronic Lymphocytic Leukemia (CLL)
    Intervention:   Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
    Sponsors:   Hackensack University Medical Center;   Celgene Corporation
    Recruiting - verified August 2014

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: decitabine;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: filgrastim;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Recurrent Childhood Acute B-lymphoblastic Leukemia;   Recurrent Childhood B-lymphoblastic Lymphoma
    Interventions:   Drug: dexamethasone;   Drug: vincristine sulfate;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: aldesleukin;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine;   Drug: cytarabine;   Drug: mitoxantrone;   Drug: teniposide;   Drug: vinblastine;   Biological: natural killer cell infusion;   Other: laboratory biomarker analysis;   Drug: therapeutic hydrocortisone;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer
    Recruiting - verified October 2014

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Ipilimumab;   Procedure: Tumor Infiltrating Lymphocytes (TIL);   Drug: Administration of Lymphodepletion;   Drug: Cyclophosphamide as Part of Lymphodepletion;   Drug: Fludarabine as Part of Lymphodepletion;   Drug: High Dose IL-2;   Biological: Adoptive Cell Therapy with TIL
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Recruiting - verified March 2015

  • Condition:   Malignant Neoplasm
    Interventions:   Biological: aldesleukin;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL;   Biological: dendritic cell vaccine therapy;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography
    Sponsor:   Jonsson Comprehensive Cancer Center
    Recruiting - verified December 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Procedure: umbilical cord blood transplantation;   Procedure: double-unit umbilical cord blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: hydroxychloroquine;   Drug: sirolimus;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Lymphoma
    Interventions:   Device: CliniMACS Fractionation system (Arm A);   Device: CliniMACS Fractionation system (Arm B)
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified March 2015

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Biological: allogeneic hematopoietic cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting - verified January 2015

  • Conditions:   Malignant Solid Tumor;   Childhood Solid Tumor
    Intervention:   Drug: Sirolimus, Cyclophosphamide, Topotecan
    Sponsors:   University of California, San Francisco;   Hyundai Hope on Wheels Foundation
    Recruiting - verified November 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Academic Myeloma Consortium;   Onyx Pharmaceuticals
    Recruiting - verified December 2014

  • Condition:   Relapsed or Refractory Systemic Light Chain Amyloidosis
    Interventions:   Drug: IXAZOMIB;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Conditions:   Glioma;   Neuroectodermal Tumors, Primitive;   Wilms Tumor;   Rhabdomyosarcoma;   Sarcoma, Ewing;   Osteosarcoma;   Retinoblastoma
    Interventions:   Drug: Metronomic Cyclophosphamide;   Drug: Thalidomide
    Sponsor:   Washington University School of Medicine
    Recruiting - verified December 2014

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting - verified February 2015

  • Conditions:   Advanced Cancers;   Leukemia
    Interventions:   Procedure: Leukapheresis;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: T-cell Infusion
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified January 2015

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Busulfan;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Condition:   Lupus Nephritis
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting - verified March 2015

  • Condition:   Systemic Lupus Erythematosus
    Interventions:   Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting - verified March 2015

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelocytic Leukemia;   Chronic Myelocytic Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Hodgkin or Non-Hodgkin Lymphoma;   Sarcoma, Myeloid
    Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: busulfan;   Drug: Plerixafor;   Drug: cyclophosphamide;   Drug: antithymocyte globulin (rabbit);   Biological: stem cells;   Drug: Tacrolimus;   Drug: mycophenolate mofetil
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified February 2015

  • Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Lymphoma;   Peripheral T-cell Lymphoma
    Interventions:   Drug: Temsirolimus;   Drug: Etoposide;   Drug: Etoposide phosphate;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Hydrocortisone;   Drug: Cytarabine
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Pfizer
    Recruiting - verified March 2015

  • Conditions:   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Childhood B Acute Lymphoblastic Leukemia;   Childhood Burkitt Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma
    Interventions:   Biological: Rituximab;   Drug: Prednisone;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Cytarabine;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Leucovorin Calcium;   Drug: Therapeutic Hydrocortisone;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Biological: Haploidentical Bone Marrow Transplant;   Biological: Double Umbilical Cord Blood Transplant
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified January 2015

  • Conditions:   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cetuximab
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Metastatic Cancer;   Pancreatic Cancer;   Mesothelioma;   Ovarian
    Interventions:   Drug: Fludarabine;   Biological: Anti-mesothelin CAR;   Drug: Cycolphosphamide;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
    Intervention:   Drug: Eribulin in Combination w/ Cyclophosphamide
    Sponsors:   University of California, San Francisco;   Eisai Inc.
    Recruiting - verified March 2015

  • Condition:   HIV
    Interventions:   Genetic: SB-728-T;   Genetic: SB-728-T;   Genetic: SB-728-T;   Genetic: SB-728-T;   Genetic: SB-728-T
    Sponsor:   Sangamo Biosciences
    Recruiting - verified March 2015

  • Conditions:   Breast Cancer;   Obesity
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Texas Tech University Health Sciences Center;   University of Texas
    Recruiting - verified February 2015

  • Conditions:   Neuroblastoma;   Sarcoma
    Intervention:   Drug: Cyclophosphamide, Topotecan, and Bevacizumab
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Genentech, Inc.;   Children's Mercy Hospital Kansas City;   Penn State University;   University of Colorado, Denver;   Sidney Kimmel Comprehensive Cancer Center;   Phoenix Children's Hospital Center for Cancer & Blood Disorders;   Alberta Children's Hospital;   MD Anderson Cancer Center Orlando;   M.D. Anderson Cancer Center
    Recruiting - verified October 2014

  • Conditions:   Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Biological: ofatumumab;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: cytarabine;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: methotrexate;   Other: laboratory biomarker analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   National Comprehensive Cancer Network;   GlaxoSmithKline
    Recruiting - verified March 2015

  • Condition:   Breast Cancer
    Interventions:   Drug: TAC chemotherapy;   Drug: TC chemotherapy;   Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy;   Drug: TCH chemotherapy;   Drug: T + trastuzumab followed by CEF + trastuzumab;   Drug: Dose dense AC followed by T + trastuzumab;   Drug: Dose dense AC followed by T + trastuzumab + pertuzumab;   Drug: PTH followed by dose dense AC of FEC
    Sponsors:   Agendia;   University of South Florida;   University of Miami;   Morton Plant Mease Health Care;   Helen Ellis Memorial Hospital;   Texas Health Plano Cancer Institute;   Ohio State University Comprehensive Cancer Center;   University of Oklahoma;   Eastchester Center for Cancer Care;   University of Southern Alabama
    Recruiting - verified October 2014

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of the Breast;   Neoplasms, Breast;   Tumors, Breast
    Interventions:   Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Emory University;   Eisai Inc.
    Recruiting - verified February 2015

  • Condition:   Sickle Cell Disease
    Intervention:   Drug: CD34 selected T-cell depleted allogeneic SCT
    Sponsors:   New York Medical College;   Children's Hospital & Research Center Oakland;   Medical College of Wisconsin;   Washington University School of Medicine;   Tufts Medical Center;   University of California, San Francisco;   University of California, Los Angeles;   Miltenyi Biotec GmbH
    Recruiting - verified January 2015

  • Conditions:   Malignant Glioma;   Glioblastoma;   Brain Cancer
    Interventions:   Biological: Anti-EGFRvIII CAR transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Scleroderma
    Interventions:   Procedure: Cytoxan rATG/Fludarabine/HSCT;   Procedure: Cytoxan rATG/HSCT
    Sponsor:   Northwestern University
    Recruiting - verified January 2015

  • Condition:   Pleuropulmonary Blastoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Doxorubicin
    Sponsor:   Children's Hospitals and Clinics of Minnesota
    Recruiting - verified February 2015

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF  (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
    Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
    Recruiting - verified February 2015

  • Condition:   Lymphoblastic Lymphoma
    Interventions:   Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine;   Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine;   Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine;   Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide;   Drug: Intrathecal chemotherapy
    Sponsors:   St. Jude Children's Research Hospital;   National University, Singapore
    Recruiting - verified November 2014

  • Condition:   Prostatic Neoplasms
    Interventions:   Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide
    Sponsor:   Georgia Regents University
    Recruiting - verified August 2014

  • Conditions:   Breast Cancer;   Metastatic Breast Cancer;   Recurrent Breast Cancer
    Interventions:   Radiation: Radiation;   Drug: Imiquimod;   Drug: Cyclophosphamide
    Sponsors:   New York University School of Medicine;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Systemic Scleroderma
    Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Other: questionnaire administration;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: mycophenolate mofetil;   Drug: plerixafor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Biological: modified T cells
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified October 2014

  • Conditions:   Leukemia;   Lymphoma;   HIV
    Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan;   Drug: Busulfan and Fludarabine;   Drug: Cyclophosphamide and Total Body Irradiation
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified March 2015

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Thomas Jefferson University
    Recruiting - verified February 2015

  • Conditions:   Light Chain Deposition Disease (LCDD or MIDD);   Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);   Monoclonal Immunoglobulin Deposition Disease (MIDD);   Amyloidosis
    Intervention:   Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2015

  • Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Preparative Regimen;   Biological: Intravenous Recombinant Human IL-15 (rhIL-15)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Inotuzumab Ozogamycin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Ara-C
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting - verified November 2014

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Preparative Regimen;   Biological: NK Cells;   Drug: Interleukin-2;   Biological: Anti-thymocyte globulin;   Biological: Donor TCR α/β-depleted Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Condition:   Chemotherapy-induced Nausea and Vomiting
    Intervention:   Drug: Palonosetron, ondansetron, dexamethasone
    Sponsors:   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified March 2015

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ofatumumab;   Drug: Methotrexate;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   GlaxoSmithKline
    Recruiting - verified October 2014

  • Condition:   Mesothelioma
    Interventions:   Drug: Pentostatin;   Drug: Cyclophosphamide;   Biological: SS1(dsFv)PE38
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Genetic: T-Cell Infusion;   Procedure: Cord Blood Infusion
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified February 2015

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Veliparib;   Drug: Cyclophosphamide;   Other: Placebo;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Thomas Jefferson University
    Recruiting - verified March 2015

  • Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
    Intervention:   Procedure: Bone Marrow Transplant
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified September 2014

  • Conditions:   Myelodysplastic Syndrome RAEB 2;   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
    Interventions:   Procedure: Allogeneic HSC Transplantation;   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Radiation: Total Body Irradiation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancy
    Interventions:   Biological: Epigenetically Modified Autologous Tumor;   Drug: Cyclophosphamide;   Drug: Celecoxib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Her2normal
    Intervention:   Drug: eribulin mesylate
    Sponsor:   Eisai Inc.
    Recruiting - verified August 2014

  • Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   Spectrum Pharmaceuticals, Inc
    Recruiting - verified March 2015

  • Conditions:   Hematologic Malignancies;   Disorder Related to Transplantation;   Hematopoietic Malignancy
    Intervention:   Genetic: Preparative Regimen
    Sponsors:   St. Jude Children's Research Hospital;   The Hartwell Foundation;   Assisi Foundation
    Recruiting - verified October 2014

  • Conditions:   Hematological Malignancies;   Leukemia;   Lymphoma;   Multiple Myeloma;   Hodgkin's Disease
    Intervention:   Device: Matched Sibling Allogeneic Transplantation
    Sponsor:   Thomas Jefferson University
    Recruiting - verified March 2015

  • Condition:   Transplant-Related Cancer
    Interventions:   Biological: Hepatitis A;   Biological: PCV 13
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Squamous Cell Carcinoma of the Oral Cavity;   Squamous Cell Carcinoma of the Soft Palate
    Interventions:   Biological: LI plus CIZ;   Other: Standard of Care (SOC);   Biological: LI + SOC
    Sponsors:   CEL-SCI Corporation;   Teva Pharmaceutical Industries;   Orient Europharma Co., Ltd.
    Recruiting - verified September 2014

  • Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Sapacitabine
    Sponsors:   M.D. Anderson Cancer Center;   Cyclacel Pharmaceuticals, Inc.
    Recruiting - verified November 2014

  • Condition:   Myeloid Hematological Malignancies
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified September 2014

  • Conditions:   Metastatic Prostate Cancer;   Cancer of the Prostate;   Prostate Cancer
    Interventions:   Drug: Anti-OX40;   Radiation: Radiation;   Drug: Cyclophosphamide
    Sponsor:   Providence Health & Services
    Recruiting - verified March 2015

  • Conditions:   Adult Supratentorial Primitive Neuroectodermal Tumor (PNET);   Childhood Supratentorial Primitive Neuroectodermal Tumor;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Peripheral Primitive Neuroectodermal Tumor of the Kidney;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
    Interventions:   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: ifosfamide;   Drug: etoposide;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Adoptive Immunotherapy;   Biological: Rapamycin-Generated Autologous Th1/Tc1 Cells
    Sponsors:   National Cancer Institute (NCI);   Hackensack University Medical Center
    Recruiting - verified February 2015

  • Conditions:   Metastatic Cancer;   Metastatic Melanoma;   Renal Cancer;   Colorectal Cancer;   Ovarian Cancer;   Lung Cancer
    Interventions:   Genetic: Anti-VEGFR2 CAR CD8 plus PBL;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: Fludarabine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Hematologic Malignancies
    Interventions:   Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified September 2014

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   AIDS-Related Diffuse Large Cell Lymphoma;   HIV Infection;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Adult Contiguous Immunoblastic Lymphoma;   Stage II Adult Non-Contiguous Immunoblastic Lymphoma;   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Contiguous Mantle Cell Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Drug: Vorinostat;   Biological: Rituximab;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: thioguanine;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Rituximab;   Biological: Interleukin-2;   Biological: Natural killer cells;   Drug: Cyclophosphamide;   Drug: Methylprednisolone;   Drug: Fludarabine
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Disseminated Neuroblastoma;   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Radiation: iobenguane I 131;   Procedure: therapeutic conventional surgery;   Drug: busulfan;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: isotretinoin;   Other: pharmacological study;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
    Interventions:   Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   DOCK8 Deficiency
    Interventions:   Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine ATG;   Drug: Busulfan (Busulfex)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Breast Cancer
    Interventions:   Biological: HER2Bi-armed activated T cells;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
    Interventions:   Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   University of Virginia;   GlasoSmithKline
    Recruiting - verified February 2015

  • Condition:   Prostate Cancer
    Interventions:   Biological: engineered autologous T cells;   Drug: cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Department of Defense
    Recruiting - verified October 2014

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified November 2014

  • Conditions:   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma
    Interventions:   Drug: liposomal vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Conditions:   Leukemia, B-cell;   Lymphoma, Hodgkins;   Lymphoma, Non-hodgkins;   Lymphoma, B-Cell
    Interventions:   Procedure: Allogeneic stem cell transplant;   Biological: Anti-CD19-chimeric-antigenreceptor- traduced T cell;   Drug: Cyclophosphamide;   Drug: Pentostatin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Pancreatic Cancer
    Intervention:   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2014

  • Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting - verified February 2015

  • Conditions:   Mucopolysaccharidosis;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy (ALD);   Krabbe Disease;   Metachromatic Leukodystrophy (MLD);   Sphingolipidoses;   Peroxisomal Disorders
    Interventions:   Drug: Campath-1H;   Drug: Cyclophosphamide;   Drug: Busulfan;   Procedure: Allogeneic stem cell transplantation;   Drug: Cyclosporine A;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors
    Interventions:   Drug: Standard Therapy;   Drug: AMG 386;   Drug: AMG 479 (Ganitumab) plus Metformin;   Drug: MK-2206 with or without Trastuzumab;   Drug: AMG 386 and Trastuzumab;   Drug: T-DM1 and Pertuzumab;   Drug: Pertuzumab and Trastuzumab;   Drug: Ganetespib
    Sponsor:   QuantumLeap Healthcare Collaborative
    Recruiting - verified October 2014

  • Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Intervention:   Biological: gene-modified T cells targeted
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified December 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Panitumumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation;   Amgen
    Recruiting - verified February 2015

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell  transplantation;   Radiation: Total body irradiation;   Procedure: Umbilical cord blood stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Conditions:   Thymoma;   Thymic Carcinoma.;   Clinical Masaoka Stage II-IVA
    Intervention:   Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Bristol-Myers Squibb;   M.D. Anderson Cancer Center;   City of Hope National Medical Center
    Recruiting - verified March 2015

  • Conditions:   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: filgrastim;   Procedure: peripheral blood stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation;   Procedure: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Blood Stem Cell Transplant Failure;   Leukemia;   Hematologic Malignancies
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa;   Drug: Tacrolimus;   Drug: Mycofenolate mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified February 2015

  • Conditions:   B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Melphalan;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
    Interventions:   Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   GlaxoSmithKline
    Recruiting - verified December 2014

  • Conditions:   Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune );   Alemtuzumab (Campath )
    Interventions:   Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath  );   Drug: Sirolimus (Rapamune  );   Drug: Cyclophosphamide (Cytoxan  );   Procedure: Low Dose Irradiation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified April 2014

  • Condition:   Breast Cancer
    Interventions:   Biological: allogeneic GM-CSF-secreting breast cancer vaccine;   Biological: trastuzumab;   Drug: cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Congenital Pediatric Disorders
    Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified February 2015

  • Conditions:   Primary Mediastinal B-cell Lymphoma;   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Renal Cell Carcinoma;   Graft-Versus-Host Disease;   Engraftment Syndrome
    Interventions:   Drug: Pentostatin;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Procedure: Th2 rapa cells
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Sarcoma
    Interventions:   Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified November 2014

  • Condition:   Metastatic Melanoma
    Interventions:   Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
    Sponsors:   Jonsson Comprehensive Cancer Center;   California Institute of Technology;   University of Southern California;   University of Connecticut;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Lymphoma
    Interventions:   Biological: G-CSF;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Mesna;   Drug: Methotrexate;   Drug: Vincristine
    Sponsor:   University of Miami
    Recruiting - verified February 2015

  • Conditions:   Neuroblastoma;   Bone Marrow, Sympathetic Nervous System
    Intervention:   Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified February 2015

  • Conditions:   Stem Cell Transplantation;   Leukemia;   Lymphoma
    Interventions:   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Busulfan;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin (ATG);   Drug: G-CSF (Filgrastim);   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Cyclophosphamide;   Drug: Mesna
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2015

  • Conditions:   Systemic Lupus Erythematosus;   Systemic Sclerosis
    Intervention:   Procedure: Nonmyeloablative allogeneic stem cell transplant
    Sponsor:   Duke University
    Recruiting - verified February 2015

  • Conditions:   Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
    Interventions:   Drug: Docetaxel and Cytoxan;   Drug: Dexamethasone
    Sponsors:   Emory University;   Sanofi
    Recruiting - verified November 2014

  • Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Biological: emepepimut-S;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Radiation: radiation therapy
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Lymphoma;   Nonneoplastic Condition
    Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem cell transplant x 1 or x 2;   Drug: lenalidomide and dexamethasone
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   Tufts Medical Center;   Lahey Clinic
    Recruiting - verified March 2015

  • Conditions:   Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Aggressive Adult Non-Hodgkin Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large B -Cell Lymphoma;   Childhood Immunoblastic Lymphoma;   Childhood Myelodysplastic Syndrome;   Childhood Nasal Type Extranodal NK/T-Cell Lymphoma;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Aggressive Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Adult T-Cell Leukemia/Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Mantle Cell Lymphoma;   Refractory Plasma Cell Myeloma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Natural Killer Cell Therapy;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Wayne D. Kuni and Joan E. Kuni Foundation;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Devic's Disease
    Intervention:   Procedure: Hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified September 2014

  • Condition:   Severe Osteopetrosis
    Interventions:   Procedure: umbilical cord blood transplantation;   Drug: Campath-1H;   Radiation: Total Lymphoid Irradiation;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Procedure: marrow graft transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified September 2014

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia
    Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
    Sponsor:   Memorial Sloan Kettering Cancer Center.
    Recruiting - verified March 2015

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2015

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Indolent Non-Hodgkin Lymphoma;   Malignant Lymphoma, Large Cell Type;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Follicular Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Umbilical Cord Blood Transplantation;   Radiation: Total-Body Irradiation;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Aggressive Non-Hodgkin Lymphoma;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   Burkitt Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia With Excess Blasts
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Conditions:   Pompe Disease;   Glycogen Storage Disease Type II (GSD-II);   Glycogenesis 2 Acid Maltase Deficiency
    Interventions:   Biological: Myozyme (alglucosidase alfa);   Biological: Myozyme (alglucosidase alfa)
    Sponsor:   Genzyme, a Sanofi Company
    Recruiting - verified December 2014

  • Conditions:   Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Radiation: total marrow irradiation;   Procedure: umbilical cord blood transplantation;   Biological: Granulocyte colony-stimulating factor;   Biological: HLA-matched related donor bone marrow
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Condition:   Melanoma
    Interventions:   Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine
    Sponsor:   Washington University School of Medicine
    Recruiting - verified February 2015

  • Conditions:   Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis;   Sickle Cell Disease;   Beta Thalassemia;   Inborn Errors of Metabolism
    Interventions:   Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
    Sponsor:   New York Medical College
    Recruiting - verified January 2015

  • Condition:   Lymphoma
    Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic stem cell transplantation;   Drug: methylprednisolone;   Drug: filgrastim;   Drug: cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
    Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified March 2015

  • Conditions:   Neuroblastoma;   Medulloblastoma
    Interventions:   Drug: Nifurtimox;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   Giselle Sholler;   Bayer
    Recruiting - verified November 2014

  • Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: Induction Chemotherapy;   Drug: Low-Risk Therapy;   Drug: High-Risk Therapy;   Drug: Intermediate-Risk Therapy
    Sponsors:   St. Jude Children's Research Hospital;   University of Florida;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: umbilical cord blood transplantation;   Drug: Allopurinol;   Drug: fludarabine phosphate;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Treg infusion;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Biological: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified March 2015

  • Condition:   Anemia, Aplastic
    Intervention:   Drug: Cyclophosphamide,Campath IH and TBI
    Sponsor:   Mayo Clinic
    Recruiting - verified October 2014

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
    Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Enzon Pharmaceuticals, Inc.
    Recruiting - verified January 2015

  • Condition:   Breast Cancer
    Interventions:   Drug: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin;   Procedure: Definitive Surgery;   Radiation: Radiotherapy
    Sponsor:   Leo W. Jenkins Cancer Center
    Recruiting - verified October 2014

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Biological: rituximab;   Drug: Methotrexate;   Drug: Sirolimus;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine sulfate;   Drug: Cytarabine;   Drug: Tacrolimus;   Biological: Alemtuzumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Leukemia;   Lymphoblastic Lymphoma;   Leukemia, Lymphoblastic, Acute
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Nelarabine
    Sponsors:   M.D. Anderson Cancer Center;   GlaxoSmithKline
    Recruiting - verified March 2015

  • Conditions:   Myelodysplastic Syndrome;   Leukemia
    Interventions:   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Rituximab;   Other: ATG;   Drug: Cyclophosphamide;   Drug: Clofarabine;   Radiation: Total Body Irradiation  (TBI);   Drug: Melphalan;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   ViaCell;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting - verified February 2015

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
    Sponsor:   Stanford University
    Recruiting - verified May 2014

  • Condition:   Leukemia
    Interventions:   Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
    Sponsors:   Memorial Sloan Kettering Cancer Center.;   National Cancer Institute (NCI)
    Recruiting - verified March 2015

  • Condition:   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Vincristine;   Genetic: RNA-based gene array studies;   Genetic: Real time PCR gene expression studies;   Genetic: Tissue-array immunohistochemical studies;   Genetic: Immunoglobulin G Fc receptor genotypes determination
    Sponsor:   University of Miami
    Recruiting - verified February 2015

  • Conditions:   Aplastic Anemia;   Non-Cancer Diagnosis
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Condition:   Lymphoma
    Interventions:   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Hematologic Neoplasms;   Neural Tube Defects;   Myeloproliferative Disorders
    Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Biological: T-Rapa cell DLI;   Procedure: T cell DLI;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified February 2015

  • Conditions:   Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total body irradiation;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2;   Drug: Mesna
    Sponsors:   M.D. Anderson Cancer Center;   Prometheus Laboratories;   Key Biologics, LLC;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Condition:   Systemic Lupus Erythematosus
    Intervention:   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified March 2015

  • Condition:   MYOPATHY
    Intervention:   Biological: hematopoietic stem cell transplantation
    Sponsor:   Northwestern University
    Recruiting - verified March 2015

  • Condition:   Multiple Sclerosis
    Interventions:   Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
    Sponsors:   Northwestern University;   Rush University Medical Center;   University of Sao Paulo;   Uppsala University;   Sheffield Teaching Hospitals NHS Foundation Trust
    Recruiting - verified March 2015

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Conditions:   Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
    Interventions:   Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified November 2014

  • Condition:   Breast Cancer
    Interventions:   Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
    Sponsors:   Baylor Breast Care Center;   Baylor College of Medicine
    Recruiting - verified November 2014

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
    Interventions:   Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Marrow Donor Program
    Recruiting - verified May 2014

  • Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Leukemia, Myeloid, Chronic;   Lymphomas;   Multiple Myeloma;   Myelodysplastic Syndrome;   Leukemia, Lymphocytic, Acute;   Leukemia, Lymphocytic, Chronic;   AML
    Interventions:   Procedure: Donor Lymphocyte Infusion;   Drug: Induction Chemotherapy + DLI
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia;   Histiocytosis
    Interventions:   Drug: Chemotherapy and antibodies;   Device: Miltenyi Biotec CliniMACS;   Procedure: Allogeneic stem cell transplantation
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting - verified January 2015

  • Conditions:   Lymphoproliferative Disorder;   HHV-8;   Malignancy;   HIV
    Interventions:   Drug: Etoposide;   Drug: Interferon-alpha;   Drug: Rituximab;   Drug: Zidovudine;   Drug: Liposomal Doxorubicin;   Drug: Bortezomib;   Drug: Valganciclovir;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Filgrastim (G-CSF);   Drug: Prednisone;   Drug: Sirolimus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Brain and Central Nervous System Tumors;   Thrombocytopenia
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide phosphate;   Drug: Etoposide;   Drug: Sodium thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Lymphoma;   Childhood Nasal Type Extranodal NK/T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Biological: Therapeutic Autologous Lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
    Intervention:   Procedure: Stem cell transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified August 2014

  • Conditions:   Lymphomatoid Granulomatosis;   Granulomatosis, Lymphomatoid;   Non-Hodgkins Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Biological: Interferon;   Drug: Rituxan and EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014


PaidClinicalTrials.orgPaidClinicalTrials.org